GENB · Intrinsic value
Is Generate Biomedicines, Inc. (GENB) overvalued or undervalued?
As of Oct 19, 2026, TickerWorth publishes a fair-value range of $1.27 – $1.27 for Generate Biomedicines, Inc. (GENB), against the delayed market price of $12.43: priced above our range. It is a range, not a single number, so we do not call it over- or undervalued. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
What is GENB worth?
- Fair-value range
- $1.27 – $1.27
- Market price
- $12.43
- Gap to fair value
- —
- Verdict
- Priced above our range
Reverse DCF, on our cash-flow model rather than the range above: Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast.
What is GENB's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: strong balance sheet. Its weakest: profitability is weak.
- Value · 32 of 100
Cheaper than 32% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 5 of 100
More profitable than 5% of Healthcare companies in US
- Financial health · 83 of 100
Financially stronger than 83% of Healthcare companies in US
- Growth · 6 of 100
Growing faster than 6% of Healthcare companies in US
- Momentum · 32 of 100
Outperformed 32% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
Why GENB gets a range, not one number
At a recent price of $12.43, Generate Biomedicines, Inc. (GENB) sits above every lens we ran: our valuation lenses put the business somewhere between $1.27 and $1.27 per share. They disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.
Read the full reasoning
The valuation discounts Generate Biomedicines, Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 10.3%, with a long-run terminal growth rate of 2.5%. About 68% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — GENB would need sustained revenue growth of more than 25%/yr to justify today's price, against about -3.1% a year compounded in our base case. We don't quote a precise figure here, because past about 25% a year the reverse-DCF stops being informative: it solves for revenue growth alone, holding margins, capital intensity and the forecast horizon fixed, so a price well above our fair value has nowhere to go but growth. The honest reading is that the price implies growth this model can't reconcile — not that we forecast it.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, GENB's modeled DCF value ranges from about $3.10 to $3.12 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Generate Biomedicines, Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of GENB's intrinsic value. Figures update as new filings and prices come in.
Every input behind GENB's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | $26,480,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 2.0% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | -10% → -6% → -3% → 0% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.10 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 128M |
| Market priceLast known price · as of 2026-10-19 17:43 UTC | $12.43 |
Change GENB's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Generate Biomedicines, Inc. do?
What does it do?
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 312 people.
How does it make money?
The business turns $26M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -1134.2%), after a 0% gross margin on the products/services it sells. After all costs, taxes and interest, 0.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.1× equity), comfortably covers its short-term bills (8.3× current ratio), and is currently lossmaking.
Who at GENB filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| ARNOLD FRANCES | Director | Open-market sale | $16,002.00 | Form 4 for ARNOLD FRANCES (opens sec.gov in a new tab) | |
| Nally Michael | Director, Chief Executive Officer | Open-market buy | $240,000.00 | Form 4 for Nally Michael (opens sec.gov in a new tab) | |
| Grous Beth | Chief People Officer | Open-market buy | $4,800.00 | Form 4 for Grous Beth (opens sec.gov in a new tab) | |
| Silvers Jason | President & CFO | Open-market buy | $8,000.00 | Form 4 for Silvers Jason (opens sec.gov in a new tab) | |
| Silvers Jason | President & CFO | Open-market buy | $8,000.00 | Form 4 for Silvers Jason (opens sec.gov in a new tab) | |
| Silvers Jason | President & CFO | Open-market buy | $16,000.00 | Form 4 for Silvers Jason (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is GENB's intrinsic value?
TickerWorth's valuation lenses put Generate Biomedicines, Inc. (GENB) between $1.27 and $1.27 per share, versus a market price of $12.43. They disagree too widely for us to state a single fair value, so we publish the range.
Is GENB overvalued or undervalued?
At $12.43 the price sits above every lens we ran. We don't call GENB overvalued or undervalued from a range this wide. This is an educational estimate, not advice.
What discount rate is used for GENB?
A WACC of 10.3% and a terminal growth rate of 2.5%.
Is Generate Biomedicines stock undervalued?
TickerWorth's fair-value range for Generate Biomedicines, Inc. (GENB) is $1.27 – $1.27 against a market price of $12.43. Priced above our range. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.
Generate Biomedicines (GENB) DCF valuation and fair value
Our fair-value range for Generate Biomedicines, Inc. (GENB) is $1.27 – $1.27, built on a 10.3% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Generate Biomedicines stock?
Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $12.43. A model estimate, not investment advice.
Generate Biomedicines (GENB) insider trading
The most recent insider filing (SEC Form 4) for Generate Biomedicines, Inc. (GENB): ARNOLD FRANCES, Director, open-market sale on 2026-09-01. The latest filings are listed on this page. A disclosure, not a signal to trade.
Other ways into the coverage
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.